Equities research analysts at StockNews.com assumed coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) in a research report issued to clients and investors on Sunday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Stock Down 1.2 %
Shares of Titan Pharmaceuticals stock opened at $3.34 on Friday. Titan Pharmaceuticals has a 12 month low of $3.03 and a 12 month high of $14.80. The stock’s fifty day simple moving average is $3.67 and its 200 day simple moving average is $4.83.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last issued its quarterly earnings data on Friday, January 3rd. The specialty pharmaceutical company reported ($0.83) EPS for the quarter.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Further Reading
- Five stocks we like better than Titan Pharmaceuticals
- What is a Secondary Public Offering? What Investors Need to Know
- 3 Defense Stocks Gaining From Budget and Interest Rate Pressures
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- 3 Natural Gas Stocks Set to Thrive in This Winter’s Freeze
- Investing In Automotive Stocks
- Bullish on Athleisure? Here’s Why Lululemon Stock Shines
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
